Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

Rhea-AI Summary

Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for degenerative retinal diseases, has announced a webcast scheduled for August 12, 2024, at 4:30 p.m. Eastern Time. The purpose of this webcast is to discuss the company's financial results for the second quarter ended June 30, 2024, and provide a business update.

Investors and interested parties can access the live webcast through the provided link or via the 'Presentations & Events' section of Belite Bio's Investor Relations website. A replay of the webcast will be available for approximately 90 days after the event, allowing those unable to attend the live session to review the information at their convenience.

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, August 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the second quarter ended June 30, 2024.

Webcast Information
Date: Monday, August 12, 2024
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Webcast Link: https://wsw.com/webcast/cc/blte4/1422018

Webcast Link Instructions
You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event.

About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at www.belitebio.com.

Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com

Julie Fallon
belite@argotpartners.com

FAQ

When will Belite Bio (BLTE) report its Q2 2024 financial results?

Belite Bio (BLTE) will report its Q2 2024 financial results and provide a business update during a webcast on Monday, August 12, 2024, at 4:30 p.m. Eastern Time.

How can investors access Belite Bio's (BLTE) Q2 2024 earnings webcast?

Investors can access Belite Bio's (BLTE) Q2 2024 earnings webcast by visiting https://wsw.com/webcast/cc/blte4/1422018 or the 'Presentations & Events' section of the company's Investor Relations website at https://investors.belitebio.com/presentations-events/events.

Will there be a replay available for Belite Bio's (BLTE) Q2 2024 earnings webcast?

Yes, a replay of Belite Bio's (BLTE) Q2 2024 earnings webcast will be available for approximately 90 days after the event on August 12, 2024.

What is the main focus of Belite Bio (BLTE)?

Belite Bio (BLTE) is a clinical-stage biopharmaceutical company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs.